Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Terence W. Friedlander

Hematology Oncology | Hematology | Oncology
UCSF Health
Ucsf Medical Group Business Services
3100 San Pablo Ave, 
Berkeley, CA 
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
UCSF Health
Ucsf Medical Group Business Services
3100 San Pablo Ave, 
Berkeley, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Terence Friedlander is a Hematologist Oncology specialist and a Hematologist in Berkeley, California. Dr. Friedlander is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Urothelial Cancer, Bladder Cancer, and Prostatectomy.

His clinical research consists of co-authoring 82 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Zuckerberg San Francisco General Hosp & Trauma Ctr
Ucsf Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UCSF MEDICAL GROUP BUSINESS SERVICES
3100 San Pablo Ave, Berkeley, CA 94702
Call: 510-985-5020
Other Locations
UNIVERSITY OF CALIFORNIA SFGH MEDICAL GROUP
1001 Potrero Ave, San Francisco, CA 94110
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
2330 Post St, San Francisco, CA 94115
Call: 415-476-4029
UCSF MEDICAL GROUP BUSINESS SERVICES
400 Parnassus Ave, San Francisco, CA 94143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Enrollment Status: Completed
Publish Date: February 25, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
A Phase I Study of Intravesical Talimogene Laherparepvec for Non-Muscle Invasive Transitional Cell Carcinoma
A Phase I Study of Intravesical Talimogene Laherparepvec for Non-Muscle Invasive Transitional Cell Carcinoma
Enrollment Status: Withdrawn
Publish Date: July 28, 2020
Intervention Type: Other, Biological
Study Phase: Phase 1
A Phase II Study of Radiation Therapy and Pembrolizumab in Patients With Localized Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy
A Phase II Study of Radiation Therapy and Pembrolizumab in Patients With Localized Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy
Enrollment Status: Withdrawn
Publish Date: December 07, 2018
Intervention Type: Radiation, Other, Biological
Study Phase: Phase 2
Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide
Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide
Enrollment Status: Terminated
Publish Date: June 26, 2018
Intervention Type: Drug
Study Phase: Phase 2
Multi-Institutional Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibition (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Muscle-Invasive or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy
Multi-Institutional Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibition (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Muscle-Invasive or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy
Enrollment Status: Withdrawn
Publish Date: October 19, 2017
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 6 Less Clinical Trials

82 Total Publications

Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma.
Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: February 06, 2025
View All 82 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arpita G. Desai
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arpita G. Desai
Hematology Oncology | Hematology | Oncology

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (11.0 miles away)
415-476-1000
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arpita Desai is a Hematologist Oncology specialist and a Hematologist in San Francisco, California. Dr. Desai has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, and Lymphadenectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sandhya S. Srinivas
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sandhya S. Srinivas
Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (29.5 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sandhya Srinivas is an Oncologist in Stanford, California. Dr. Srinivas is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Endoscopy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sumit A. Shah
Oncology | Hematology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sumit A. Shah
Oncology | Hematology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (29.5 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sumit Shah is an Oncologist and a Hematologist in Stanford, California. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), and Gastrostomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Friedlander's expertise for a condition
ConditionClose
  • Elite
  • Bladder Cancer
    Dr. Friedlander is
    Elite
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Familial Prostate Cancer
    Dr. Friedlander is
    Elite
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Prostate Cancer
    Dr. Friedlander is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Urothelial Cancer
    Dr. Friedlander is
    Elite
    . Learn about Urothelial Cancer.
    See more Urothelial Cancer experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Friedlander is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Friedlander is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Friedlander is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Muscle Invasive Bladder Cancer
    Dr. Friedlander is
    Distinguished
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Friedlander is
    Distinguished
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • WT1-Related Wilms Tumor Syndromes
    Dr. Friedlander is
    Distinguished
    . Learn about WT1-Related Wilms Tumor Syndromes.
    See more WT1-Related Wilms Tumor Syndromes experts
  • Advanced
  • Choriocarcinoma
    Dr. Friedlander is
    Advanced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Familial Wilms Tumor 2
    Dr. Friedlander is
    Advanced
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Metastatic Brain Tumor
    Dr. Friedlander is
    Advanced
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
  • Nasopharyngeal Carcinoma
    Dr. Friedlander is
    Advanced
    . Learn about Nasopharyngeal Carcinoma.
    See more Nasopharyngeal Carcinoma experts
  • Posterior Fossa Tumor
    Dr. Friedlander is
    Advanced
    . Learn about Posterior Fossa Tumor.
    See more Posterior Fossa Tumor experts
  • Primitive Neuroectodermal Tumor (PNET)
    Dr. Friedlander is
    Advanced
    . Learn about Primitive Neuroectodermal Tumor (PNET).
    See more Primitive Neuroectodermal Tumor (PNET) experts
View All 9 Advanced Conditions
  • Experienced
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Friedlander is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Anal Cancer
    Dr. Friedlander is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Friedlander is
    Experienced
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Colorectal Cancer
    Dr. Friedlander is
    Experienced
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • EGFR Positive Lung Cancer
    Dr. Friedlander is
    Experienced
    . Learn about EGFR Positive Lung Cancer.
    See more EGFR Positive Lung Cancer experts
  • Epithelial-Myoepithelial Carcinoma
    Dr. Friedlander is
    Experienced
    . Learn about Epithelial-Myoepithelial Carcinoma.
    See more Epithelial-Myoepithelial Carcinoma experts
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved